The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
Open accessAbstract
This study evaluates the efficacy of capecitabine using data from a large, well-characterised population of patients with metastatic colorectal cancer (mCRC) treated in two identically designed phase III studies. A total of 1207 patients with previously untreated mCRC were randomised to either oral capecitabine (1250 mg m(-2) twice daily, days 1-14 every 21 days; n=603) or intravenous (i.v.) bolus 5-fluorouracil/leucovorin (5-FU/LV; Mayo Clinic regimen; n=604). Capecitabine demonstrated a statistically significant superior response rate compared with 5-FU/LV (26 vs 17%; P<0.0002). Subgroup analysis demonstrated that capecitabine consistently resulted in superior response rates (P<0.05), even in patient subgroups with poor prognostic indicators. The median time to response and duration of response were similar and time to progression (TTP) was equivalent in the two arms (hazard ratio (HR) 0.997, 95% confidence interval (CI) 0.885-1.123, P=0.95; median 4.6 vs 4.7 months with capecitabine and 5-FU/LV, respectively). Multivariate Cox regression analysis identified younger age, liver metastases, multiple metastases and poor Karnofsky Performance Status as independent prognostic indicators for poor TTP. Overall survival was equivalent in the two arms (HR 0.95, 95% CI 0.84-1.06, P=0.48; median 12.9 vs 12.8 months, respectively). Capecitabine results in superior response rate, equivalent TTP and overall survival, an improved safety profile and improved convenience compared with i.v. 5-FU/LV as first-line treatment for MCRC. For patients in whom fluoropyrimidine monotherapy is indicated, capecitabine should be strongly considered. Following encouraging results from phase I and II trials, randomised trials are evaluating capecitabine in combination with irinotecan, oxaliplatin and radiotherapy. Capecitabine is a suitable replacement for i.v. 5-FU as the backbone of colorectal cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815 · cited 1×
“…clinical studies have demonstrated that oxaliplatin in combination with infused 5-FU/LV is a highly effective first-line treatment for patients with advanced colorectal cancer, resulting in superior response rates and TTP compared with 5-FU/LV alone (de Gramont et al, 2000; Giacchetti et al, 2000).”
BackgroundDouillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Self-citationIrinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationGoldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Self-citationMiwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Self-citationVan Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
Self-citationRougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03085-2 · Cited by 992
Self-citationPatient preferences for oral versus intravenous palliative chemotherapy.
Liu, G., Franssen, E., Fitch, M. I., & Warner, E. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.110 · Cited by 919
Sch�ller, J., Cassidy, J., Dumont, E., Roos, B., Banken, L., Mori, K., Reigner, B., Utoh, M., Weidekamm, E., & Durston, S. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050043 · Cited by 534
Köhne, C.-H., Cunningham, D., Di Costanzo, F., Glimelius, B., Blijham, G., Aranda, E., Scheithauer, W., Rougier, P., Palmer, M., Wils, J., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf034 · Cited by 464
Self-citationCassidy, J., Twelves, C., Van Cutsem, E., Hoff, P., Bajetta, E., Boyer, M., Bugat, R., Burger, U., Garin, A., Graeven, U., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf089 · Cited by 425
Self-citationRothenberg, M. L., Meropol, N. J., Poplin, E. A., Van Cutsem, E., & Wadler, S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3801 · Cited by 425
Clinical Pharmacokinetics of Capecitabine
Reigner, B., Blesch, K., & Weidekamm, E. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140020-00002 · Cited by 388
Douillard, J.-Y., Hoff, P. M., Skillings, J. R., Eisenberg, P., Davidson, N., Harper, P., Vincent, M. D., Lembersky, B. C., Thompson, S., Maniero, A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.123 · Cited by 323
Self-citationSawada, N., Ishikawa, T., Sekiguchi, F., Tanaka, Y., & Ishitsuka, H. (1999) · PubMed · Cited by 319
Van Cutsem, E., Findlay, M., Osterwalder, B., Kocha, W., Dalley, D., Pazdur, R., Cassidy, J., Dirix, L., Twelves, C., Allman, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1337 · Cited by 318
Borner, M. M., Schöffski, P., de Wit, R., Caponigro, F., Comella, G., Sulkes, A., Greim, G., Peters, G. J., van der Born, K., Wanders, J., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00371-9 · Cited by 316
Maindrault-Goebel, F., Louvet, C., André, T., Carola, E., Lotz, J. P., Molitor, J. L., Garcia, M. L., Gilles-Amar, V, Izrael, V, Krulik, M., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00149-5 · Cited by 290
André, T., Bensmaine, M. A., Louvet, C., François, E., Lucas, V., Desseigne, F., Beerblock, K., Bouché, O., Carola, E., Merrouche, Y., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3560 · Cited by 277
Twelves, C., Boyer, M., Findlay, M., Cassidy, J., Weitzel, C., Barker, C., Osterwalder, B., Jamieson, C., & Hieke, K. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00444-5 · Cited by 158
Capecitabine as first-line treatment in colorectal cancer
Twelves, C. J. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00415-4 · Cited by 139
Schilsky, R. L., Levin, J., West, W. H., Wong, A., Colwell, B., Thirlwell, M. P., Ansari, R., Bell, W. N., White, R. L., Yates, B. B., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1519 · Cited by 83
Self-citationIrinotecan Dosing: Does the CPT in CPT-11 Stand for “Can’tPredictToxicity”?
Ratain, M. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.1.7 · Cited by 60
Patt, Y. Z., Lee, F.-C., Liebmann, J. E., Diamandidis, D., Eckhardt, S., Javle, M. M., Justice, G. R., Keiser, W., Salvatore, J. R., Bexon, A. S., et al. (2007) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31804b40bb · Cited by 52
Schmoll, H. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200310000-00003 · Cited by 22
Cited by
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Self-citationCervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Cederquist, L., Chan, E., Chen, Y.-J., Cooper, H. S., Deming, D., Engstrom, P. F., Enzinger, P. C., Fichera, A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0036 · Cited by 1,330
Metadata
- Authors
- Cutsem, E. V., Hoff, P. M., Harper, P., Bukowski, R. M., Cunningham, D., Dufour, P., Graeven, U., Lokich, J., Madajewicz, S., Maroun, J. A., Marshall, J. L., Mitchell, E. P., Perez-Manga, G., Rougier, P., Schmiegel, W., Schoelmerich, J., Sobrero, A., & Schilsky, R. L.
- Venue
- British Journal of Cancer
- Published
- 2004-02-24
- Volume
- 90
- Issue
- 6
- Pages
- 1190-1197
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2084330540
- Cited by
- 401
- References
- 28
- FWCI
- 18.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.